Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Orthopediatrics (KIDS) Shares Outstanding (Diluted Average) (2019 - 2026)

Orthopediatrics has reported Shares Outstanding (Diluted Average) over the past 8 years, most recently at $23.7 million for Q1 2026.

  • For Q1 2026, Shares Outstanding (Diluted Average) rose 1.96% year-over-year to $23.7 million; the TTM value through Mar 2026 reached $23.7 million, up 1.96%, while the annual FY2025 figure was $23.5 million, 1.65% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q1 2026 was $23.7 million at Orthopediatrics, up from $23.5 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $23.7 million in Q1 2026 and troughed at $19.4 million in Q1 2022.
  • A 5-year average of $22.4 million and a median of $22.8 million in 2024 define the central range for Shares Outstanding (Diluted Average).
  • Biggest five-year swings in Shares Outstanding (Diluted Average): grew 0.87% in 2022 and later grew 16.21% in 2023.
  • Year by year, Shares Outstanding (Diluted Average) stood at $20.9 million in 2022, then increased by 8.25% to $22.7 million in 2023, then rose by 1.77% to $23.1 million in 2024, then grew by 1.65% to $23.5 million in 2025, then rose by 0.96% to $23.7 million in 2026.
  • Business Quant data shows Shares Outstanding (Diluted Average) for KIDS at $23.7 million in Q1 2026, $23.5 million in Q4 2025, and $23.6 million in Q3 2025.